Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 7/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 9/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.56 |
| ▸ | KIF11 | P52732 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764818 | 1.00 | TP53 (0.60) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| SCHEMBL8403046 | 0.95 | TP53 (0.55) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| Emvododstat SCHEMBL29965534 | 0.95 | TP53 (0.62) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| SCHEMBL15087042 | 0.95 | TP53 (0.62) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| Emvododstat SCHEMBL29382728 | 0.95 | TP53 (0.62) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| Emvododstat SCHEMBL764056 | 0.95 | TP53 (0.62) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| Emvododstat SCHEMBL8509210 | 0.95 | TP53 (0.62) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| Emvododstat SCHEMBL9962251 | 0.95 | TP53 (0.62) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| SCHEMBL22238592 | 0.95 | TP53 (0.54) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| SCHEMBL8403043 | 0.95 | TP53 (0.60) | TP53MAPTSMN1; SMN2ABCG2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172915-A1 | DHODH INHIBITOR FOR THE TREATMENT OF COVID-19 | PTC THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120136154-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED TETRAHYDRO BETA-CARBOLINES | PTC THERAPEUTICS, INC. | 2012-05-31 | — | — | US | disclosed |
| US-8076352-B2 | Administration of carboline derivatives useful in the treatment of cancer and other diseases | PTC THERAPEUTICS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20100179132-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172915-A1 | DHODH INHIBITOR FOR THE TREATMENT OF COVID-19 | DHODH, ACE2, DHRS9 | TP53 4232/4885MAPT 3213/4885SMN1; SMN2 3429/4885 |
| US-20100179132-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | VEGFA, FLT4, PGF | TP53 166/4885MAPT 4804/4885SMN1; SMN2 4588/4885 |
| US-20120136154-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED TETRAHYDRO BETA-CARBOLINES | TPH1, TPH2, HTR1B | TP53 4290/4885MAPT 1428/4885SMN1; SMN2 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.